, WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2008.
, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015
, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur J Cancer, vol.49, pp.1374-403, 2013.
, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBO-CAN 2012, Int J Cancer, vol.136, pp.359-86, 2015.
, Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network, Br J Cancer, vol.112, pp.1575-84, 2015.
, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002.
, French Network of Cancer Registries (FRANCIM)Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France, Int J Cancer, vol.132, pp.2378-87, 2013.
, Contributions of subtypes of non-Hodgkin lymphoma to mortality trends, Cancer Epidemiol Biomark Prev, vol.25, pp.174-183, 2016.
, Cancer incidence and survival in adolescents and young adults in France, Pediatr Hematol Oncol, vol.30, pp.291-306, 2000.
URL : https://hal.archives-ouvertes.fr/hal-02168116
, The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry, Leuk Lymphoma, vol.56, pp.1050-1057, 2015.
, Cancer incidence in France over the 1980-2012 period: hematological malignancies, Rev Epidemiol Sante Publique, vol.64, pp.103-115, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580
, Chronic myeloid leukemia: advances in biology and new approaches to treatment, N Engl J Med, vol.349, pp.1451-64, 2003.
, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, pp.2516-2536, 2008.
, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood, vol.123, pp.2293-301, 2014.
, Targeted therapy in haematological malignancies, J Pathol, vol.220, pp.404-422, 2010.
, Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists, Pathology, vol.48, pp.5-16, 2016.
, The emerging role of PI3K inhibitors in the treatment of hematological malignancies: preclinical data and clinical progress to date, Drugs, vol.76, pp.639-685, 2016.
, Novel agents versus chemotherapy as frontline treatment of CLL, Leuk Lymphoma, vol.58, pp.1320-1324, 2017.
, Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype, Clin Cancer Res, vol.20, pp.5182-93, 2014.
, Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma, Cancer Genet, vol.206, pp.257-65, 2013.
, Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research, BMJ, vol.347, p.6409, 2013.
, Cancer trials versus the real world in the United States, Ann Surg, vol.254, pp.438-480, 2011.
, Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved?, Cancer, vol.119, pp.2956-63, 2013.
, Effort required in eligibility screening for clinical trials, J Oncol Pract, vol.8, pp.365-70, 2012.
, Evaluation of algorithms to identify incident cancer cases by using French health administrative databases, Pharmacoepidemiol Drug Saf, vol.26, pp.935-979, 2017.
, Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database, Eur J Intern Med, vol.32, pp.21-23, 2016.
, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, pp.3308-3323, 2014.
, Identifying multiple myeloma patients using data from the French health insurance databases: validation using a cancer registry, Medicine (Baltimore), vol.96, p.6189, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907563
, Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients, Pharmacoepidemiol Drug Saf, vol.26, pp.1492-1501, 2017.
, Validation of a medicare claims-based algorithm for identifying breast cancers detected at screening mammography, Med Care, vol.54, pp.15-22, 2016.
, EU-ADR consortiumHarmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc, vol.20, pp.184-92, 2013.
, Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.82-91, 2012.
, Estimation of national colorectalcancer incidence using claims databases, J Cancer Epidemiol, vol.2012, p.298369, 2012.
, Evaluation of an algorithm to identify incident breast cancer cases using DRGs data, Eur J Cancer Prev, vol.12, pp.295-304, 2003.
, French claims data as a source of information to describe cancer incidence: predictive values of two identification methods of incident prostate cancers, J Med Syst, vol.30, pp.459-63, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00427927
, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952
, Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France, Rev Dépidémiologie Santé Publique, vol.54, pp.391-399, 2006.
, Predictive value and sensibility of hospital discharge system (PMSI) compared to cancer registries for thyroïd cancer, Rev Dépidémiologie Santé Publique, vol.54, pp.367-76, 1999.
, Performance evaluation of hospital claims database for the identification of incident central nervous system tumors compared with a cancer registry, Rev DÉpidémiologie Santé Publique, vol.60, pp.295-304, 2004.
, Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data, Cancer Causes Control, vol.18, pp.561-570, 2007.
, Registre des cancers du Tarn (registre qualifié 2010-2013) /Portail Epidemiologie -France j Health Databases, 2017.
, , 2017.
, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.203-215, 2012.
, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, pp.5446-56, 2008.
, Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup, Ann Oncol, vol.24, issue.6, pp.149-54, 2013.
, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.70-75, 2014.
, Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset, J Cancer Res Clin Oncol, vol.142, pp.167-75, 2016.
, Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.
, Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis, 2010.
, Ann Oncol, vol.21, pp.925-930
, Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interviewbased studies, Lancet Oncol, vol.12, issue.11, p.70002, 2011.
, The faster the better?-a systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways, Psychooncology, vol.21, pp.1-10, 2012.
, Managing psychological morbidity in cancer patients, Eur J Cancer Oxf Engl, vol.36, pp.556-558, 1990.
, Treatment of depression in cancer, J Natl Cancer Inst Monogr, pp.105-111, 2004.
, Anxiety and depression in cancer patients compared with the general population, Eur J Cancer Care (Engl), vol.19, pp.522-529, 2010.
, La dépression en oncologie, Cancer/Radiothérapie, vol.14, pp.535-538, 2010.
, Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study, Br J Cancer, vol.107, pp.1644-1651, 2012.
, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psycho-Oncology, vol.22, pp.762-767, 2013.
, Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma, Cancer, vol.119, pp.672-680, 2013.
, The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the, 2014.
, Prevalence and factors associated with polypharmacy in older people with cancer, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.22, pp.1727-1761, 2014.
, Polypharmacy and drug use in elderly Danish cancer patients during 1996 to, J Geriatr Oncol, vol.3, pp.33-40, 2006.
, Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development, Mol Pharm, vol.10, pp.4055-62, 2013.
, Injustifiable use of gastroprotection in advanced cancer patients, Palliat Med, vol.21, pp.631-634, 2007.
, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications, Am J Gastroenterol, vol.104, pp.728-766, 2009.
, Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review, Curr Med Res Opin, vol.2017, pp.1-8
, Haute Autorité de Santé -Les inhibiteurs de la pompe à protons chez l'adulte -Fiche BUM n, 2017.
, Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients, Am J Gastroenterol, vol.101, pp.2200-2205, 2006.
, Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease, JAMA, vol.294, pp.2989-95, 2005.
, Adverse effects of long-term proton pump inhibitor therapy, Dig Dis Sci, vol.56, 2011.
, Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, pp.1706-1719, 2016.
, The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association, Gastroenterology, vol.152, pp.706-721, 2017.
, PharmacistBarney's LTC PharmacyAugusta
, BCPSClinical Pharmacy Educator, Barney's PharmacyClinical Assistant ProfessorUniversity of Georgia College of PharmacyAugusta. Long-Term Consequences of Chronic Proton Pump Inhibitor Use n, PharmDPGY-2Community/Academia Pharmacy ResidentKerr Drug/UNC School of PharmacyChapel Hill, North Carolina John A Galdo, PharmD, 2017.
, Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center
, Ann Pharmacother, vol.50, pp.541-548, 2016.
, The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients, Int J Clin Pharm, vol.37, pp.1152-61, 2015.
, Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use, Crit Rev Oncol Hematol, vol.111, pp.144-51, 2017.
, Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update, Drug Saf, vol.37, pp.201-212, 2014.
, Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors, The Oncologist, vol.17, pp.550-554, 2012.
, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol, vol.30, pp.616-640, 2016.
, Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non
, Hodgkin's lymphoma: a cohort study of the French national health insurance database
, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.
, Evaluation of an algorithm to identify incident Non-Hodgkin's lymphoma cases using claims databases with cancer registry. Poster session presented at: Group of Registry and Epidemiology of Cancer in Latin Speaking Countries, 2006.
,
, Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs
, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, pp.855-61, 2009.
,
, Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period, Aliment Pharmacol Ther, vol.44, pp.78-87, 2016.
, Indications and safety of proton pump inhibitor drug use in patients with cancer, Expert Opin Drug Saf, vol.12, pp.659-72, 2013.
, Factors associated with the initiation of proton pump inhibitors in corticosteroid users, Pharmacoepidemiol Drug Saf, vol.21, pp.366-74, 2012.
, A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians, Scand J Gastroenterol, vol.45, pp.1156-61, 2010.
, Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy
, Br J Clin Pharmacol, vol.68, pp.252-261, 2009.
, Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients, PloS One, vol.10, p.141779, 2015.
, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J Intern Med, vol.236, pp.619-651, 1994.
, Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use, Crit Rev Oncol Hematol, vol.111, pp.144-51, 2017.
, Overutilization of proton-pump inhibitors: what the clinician needs to know, Ther Adv Gastroenterol, vol.5, pp.219-251, 2012.
, Stress Ulcer Prophylaxis in Hospitalized Patients, Subsequent Use in Primary Care, and Physicians' Opinions About Acid-Suppressive Therapy, South Med J, vol.109, pp.158-64, 2016.
,
, Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship, Cancer. 15 mars, vol.122, issue.6, pp.954-61, 2016.
, Risk and predictors of attempted and completed suicide in patients with hematological malignancies
, Psychooncology, vol.23, issue.1, pp.1276-82, 2014.
,
, Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study, Cancer. 15 avr, vol.109, issue.8, pp.1659-67, 2007.
, Post-Traumatic Stress Outcomes in Non-Hodgkin's Lymphoma Survivors, J Clin Oncol, vol.20, issue.6, pp.934-975, 2008.
, The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv Res Pract. déc, vol.8, issue.4, pp.555-64, 2014.
,
, Quality of life amongst lymphoma survivors in a developing country, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. déc, vol.24, issue.12, pp.5015-5038, 2016.
, Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non
, Hodgkin's lymphoma: a cohort study of the French national health insurance database
, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.
, Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia, Asian Pac J Cancer Prev APJCP, vol.15, issue.10, pp.4261-4265, 2014.
, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf. 24 mai, 2017.
, French health insurance databases: What interest for medical research, Rev Med Interne. juin
, French national health insurance information system and the permanent beneficiaries sample, Rev Epidemiol Sante Publique. août, vol.58, issue.4, pp.286-90, 2010.
, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol. déc, vol.30, issue.6, pp.616-640, 2016.
, Evaluation of an algorithm to identify incident Non-Hodgkin's lymphoma cases using claims databases with cancer registry. Conference Poster présenté à: GRELL; 2016 mai, p.137
, Ecological association between a deprivation index and mortality in France over the period 1997 -2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death, 2009.
, The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, vol.54, pp.188-194, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541
, Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors, Br J Cancer, vol.76, issue.6, pp.791-797, 1997.
,
, Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma, Cancer. 1 févr, vol.119, issue.3, pp.672-80, 2013.
, Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study
, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.11, pp.1906-1919, 2015.
, Benzodiazepines and risk of death: Results from two large cohort studies in France and UK, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.10, pp.1566-77, 2015.
,
, Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD
, Eur Respir J. août, vol.44, issue.2, pp.332-372, 2014.
, Haute Autorité de Santé -ALD n° 30 -Lymphomes non hodgkiniens de l'adulte
, Haute autorité de santé, 2015.
,
, Estimation nationale de l'incidence et de la mortalté par cancer en France entre 1980 et 2012. Partie 2 -Hémopathies malignes, 2013.
,
, Non-Hodgkin lymphoma, Lancet Lond Engl. 1 sept, vol.380, issue.9844, pp.848-57, 2012.
, Hodgkin Lymphoma, Version 2, J Natl Compr Cancer, vol.13, issue.5, pp.554-86, 2015.
, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, Int J Cancer, vol.136, issue.5, pp.359-86
, Lymphoma -Cancer Stat Facts
,
, The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry, Leuk Lymphoma, vol.56, issue.4, pp.1050-1057, 2015.
, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur J Cancer, vol.49, issue.6, pp.1374-403
, Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique. avr, vol.64, issue.2, pp.103-115, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580
, Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network
, Br J Cancer. 28 avr, vol.112, issue.9, pp.1575-84, 2015.
, Cancer incidence and survival in adolescents and young adults in France, Pediatr Hematol Oncol. mai, vol.30, issue.4, pp.291-306, 2000.
URL : https://hal.archives-ouvertes.fr/hal-02168116
, Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph), vol.110, pp.695-708, 2007.
, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues -Google Livres, 2001.
,
, Survie nette des personnes atteintes de cancer en France, 1989.
,
, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011.
, InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions, vol.116, 2010.
, Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in FranceMonnereau -2012 -International Journal of Cancer -Wiley Online Library, vol.132, pp.2378-87, 2013.
, Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review, World J Gastroenterol. 14 juill, vol.21, issue.26, pp.8014-8034, 2015.
, Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?, Semin Cancer Biol. févr, vol.24, pp.61-70, 2014.
, HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options, Hematol Am Soc Hematol Educ Program. 5 déc, vol.2014, issue.1, pp.584-593, 2014.
, Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management, Br J Haematol. févr, vol.168, issue.3, pp.317-344, 2015.
, Hepatitis C virus and lymphoma, Crit Rev Oncol Hematol. mars, vol.93, issue.3, pp.246-56, 2015.
, Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment, World J Gastroenterol. 28 août, vol.20, issue.32, pp.11054-61, 2014.
, The Epstein-Barr virus and the pathogenesis of lymphoma, J Pathol. janv, vol.235, issue.2, pp.312-334, 2015.
, Risk factors for etiology and prognosis of mantle cell lymphoma, Expert Rev Hematol. avr, vol.7, issue.2, pp.233-276, 2014.
, An update of the epidemiology of non-Hodgkin's lymphoma, Clin Lymphoma. déc, vol.4, issue.3, pp.161-169, 2003.
, Occupational trichloroethylene exposure and non-Hodgkin's lymphoma: a meta-analysis and review, Occup Environ Med. sept, vol.63, issue.9, pp.597-607, 2006.
, Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study, Occup Environ Med. févr, vol.70, issue.2, pp.91-99, 2013.
, Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis, Int J Environ Res Public Health. 23 avr, vol.11, issue.4, pp.4449-527, 2014.
, Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management, Am J Hematol. juill, vol.89, issue.7, pp.771-780, 2014.
, Non-Hodgkin lymphoma. The Lancet, vol.15, pp.298-310, 10091.
, Les apports des Plans cancer à la cancérologie. Oncologie [Internet]. sept, vol.16, pp.4-6, 2014.
, Oncomip -Référentiel-Traitement des lymphomes de l'adulte, 2012.
,
, , 2013.
, Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. oct, vol.24, issue.6, pp.149-154, 2013.
, Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup, Ann Oncol Off J Eur Soc Med Oncol. 1 juill, vol.28, issue.suppl_4, pp.62-71, 2017.
, Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis
, Ann Oncol Off J Eur Soc Med Oncol. 19 févr, 2017.
, Extranodal diffuse large Bcell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.27, issue.5, pp.91-102, 2016.
, Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.26, issue.5, pp.108-115, 2015.
, Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.25, issue.3, pp.83-92, 2014.
, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. sept, vol.25, issue.3, pp.70-75, 2014.
, ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), Ann Oncol Off J Eur Soc Med Oncol. mars, vol.24, issue.3, pp.561-76, 2013.
, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med. 24 janv, vol.346, issue.4, pp.235-277, 2002.
, IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients -Nguyen -2009 -European Journal of Haematology -Wiley Online Library, Disponible sur, vol.62, pp.76-82, 1999.
, The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer [Internet]. 1 févr, vol.15, pp.179-85, 2007.
, Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients, Psychooncology [Internet]. 1 mars, 2014.
,
, Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial, Clin Lymphoma Myeloma Leuk. juin, vol.12, issue.3, pp.151-155, 2012.
, Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment, Bull Cancer, vol.104, issue.3, pp.221-252, 2017.
, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte, Blood [Internet], vol.116, issue.12, pp.2040-2045, 2010.
, Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.23, issue.18, pp.4117-4143, 2005.
, Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century, Arch Intern Med, vol.168, issue.5, pp.469-76, 2008.
, Rituximab chimeric anti-CD20 monoclonal antibod, J Clin Oncol, vol.16, issue.8, pp.2825-2858, 1998.
, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood. 10 avr, vol.123, issue.15, pp.2293-301, 2014.
, Hodgkin Lymphoma -Cancer Stat Facts
,
, Chronic myeloid leukemia--advances in biology and new approaches to treatment, N Engl J Med, vol.349, issue.15, pp.1451-64, 2003.
, Improved survival in multiple myeloma and the impact of novel therapies, Blood. 1 mars, vol.111, issue.5, pp.2516-2536, 2008.
, Targeted therapy in haematological malignancies, J Pathol. mars, vol.220, issue.4, pp.404-422, 2010.
, Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists, Pathology (Phila). janv, vol.48, issue.1, pp.5-16, 2016.
, The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date, Drugs [Internet]. 1 avr, vol.76, issue.6, pp.639-685, 2016.
, Novel agents versus chemotherapy as frontline treatment of CLL, Leuk Lymphoma. juin, vol.58, issue.6, pp.1320-1324, 2017.
, Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, issue.20, pp.5182-93, 2014.
, Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma, Cancer Genet. août, vol.206, issue.7-8, pp.257-65, 2013.
, Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research, BMJ, vol.347, issue.11, 2013.
, Cancer trials versus the real world in the United States, Ann Surg. sept, vol.254, issue.3, pp.442-443, 2011.
, Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?, Cancer. 15 août, vol.119, issue.16, pp.2956-63, 2013.
, Effort required in eligibility screening for clinical trials, J Oncol Pract, vol.8, issue.6, pp.365-70, 2012.
,
, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf. 24 mai, 2017.
, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol. déc, vol.30, issue.6, pp.616-640, 2016.
, French health insurance databases: What interest for medical research, Rev Med Interne. juin, vol.36, issue.6, pp.411-418, 2015.
, French national health insurance information system and the permanent beneficiaries sample, Rev Epidemiol Sante Publique. août, vol.58, issue.4, pp.286-90, 2010.
, Résultats de la recherche -Ministère des Solidarités et de la Santé
,
, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, issue.22, pp.3308-3323, 2014.
, Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database, Eur J Intern Med. juill, vol.32, pp.21-22, 2016.
, Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study, PLoS ONE, vol.10, issue.11, 2015.
,
, Rev Epidemiol Sante Publique, vol.65, issue.4, pp.144-152, 2017.
, Ecological association between a deprivation index and mortality in France over the period 1997 -2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death, vol.22, p.33
, The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality. Med Care, vol.54, pp.188-194
URL : https://hal.archives-ouvertes.fr/hal-01817541
, Value of a national administrative database to guide public decisions: From the système national, p.161
, Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, Rev Epidemiol Sante Publique. 26 juill, 2017.
, Data validity issues in using claims data, Pharmacoepidemiol Drug Saf. sept, vol.10, issue.5, pp.389-92, 2001.
, Public Policy Committee IS of P. Guidelines for good pharmacoepidemiology practice (GPP)
, Pharmacoepidemiol Drug Saf, vol.1, issue.2016, pp.2-10
, Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures, Pharmacoepidemiol Drug Saf. mars, vol.25, issue.1, pp.88-102, 2016.
, Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project, Curr Clin Pharmacol. mai, vol.9, issue.2, pp.130-138, 2014.
, Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies, Ther Adv Drug Saf. avr, vol.4, issue.2, pp.53-62, 2013.
, Misclassification of current benzodiazepine exposure by use of a single baseline measurement and its effects upon studies of injuries, Pharmacoepidemiol Drug Saf. déc, vol.11, issue.8, pp.663-672, 2002.
, Patterns of bias due to differential misclassification by case-control status in a casecontrol study, Eur J Epidemiol, vol.22, issue.1, pp.7-17, 2007.
, Bias from nondifferential misclassification in case-control studies with three exposure levels, Epidemiol Camb Mass. mai, vol.6, issue.3, pp.276-81, 1995.
, Effect of nondifferential misclassification on estimates of odds ratios with multiple levels of exposure, Am J Epidemiol. 1 août, vol.136, issue.3, pp.356-62, 1992.
, Good practices for quantitative bias analysis, Int J Epidemiol. déc, vol.43, issue.6, pp.1969-85, 2014.
, Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?, Pharmacoepidemiol Drug Saf. mai, vol.26, issue.5, pp.544-53, 2017.
, Estimation of national colorectal-cancer incidence using claims databases, J Cancer Epidemiol, p.298369, 2012.
, A high positive predictive value algorithm using hospital administrative data identified incident cancer cases, J Clin Epidemiol, vol.61, issue.4, pp.373-382, 2008.
, Critical analysis of French DRG based information system (PMSI) databases for the epidemiology of cancer
, Rev Dépidémiologie Santé Publique. févr, vol.59, issue.1, pp.53-61, 2011.
, A Suitable Approach to Estimate Cancer Incidence in Area without Cancer Registry, J Cancer Epidemiol, p.418968, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00698065
, Evaluation of an algorithm to identify incident breast cancer cases using DRGs data, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. août, vol.12, issue.4, pp.295-304, 2003.
, French claims data as a source of information to describe cancer incidence: predictive values of two identification methods of incident prostate cancers, J Med Syst. déc, vol.30, issue.6, pp.459-63, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00427927
, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, issue.10, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952
, Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France
, Rev Dépidémiologie Santé Publique, vol.54, pp.391-399, 2006.
, Predictive value and sensibility of hospital discharge system (PMSI) compared to cancer registries for thyroïd cancer, Rev Dépidémiologie Santé Publique. sept, vol.54, issue.4, pp.367-76, 1999.
, Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data, Cancer Causes Control CCC. juin, vol.18, issue.5, pp.561-570, 2007.
, Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry, Medicine (Baltimore). mars, vol.96, issue.12, p.6189, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907563
, Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc JAMIA. 1 janv, vol.20, issue.1, pp.184-92, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01135052
, Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned, Pharmacoepidemiol Drug Saf. janv, vol.21, issue.1, pp.82-91, 2012.
, Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.
,
, Registre des cancers du Tarn (registre qualifié 2010-2013) / Portail Epidemiologie -France | Health Databases
,
, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf. janv, vol.21, issue.1, pp.203-215, 2012.
, The effect of an ambulatory medical assistance during chemotherapy and follow-up among patient with diffuse large B-cell lymphoma on treatment adherence, J Clin Oncol, vol.32, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01933497
, Psychopharmacology in psycho-oncology, Curr Psychiatry Rep. sept, vol.15, issue.9, p.393, 2013.
, Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study, British Journal of Cancer, vol.107, pp.1644-51, 2012.
, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psycho-Oncology, vol.1, issue.2013, pp.762-769
, Rapport sur le bon usage des médicaments psychotropes, Juin, 2006.
, Améliorer la prescription des psychotropes chez le sujet âgé, une démarche participative de la Haute autorité de santé. Numéro thématique. La santé mentale en France, surveillance et enjeux, p.328, 2008.
, Reich M. La dépression en oncologie. Cancer/Radiothérapie, 2010.
, The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a populationbased cohort, Thorax. févr, vol.68, issue.2, pp.163-70, 2013.
, Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis, Ann Oncol, vol.21, issue.5, 2010.
, Hospital prescribing and usage of hypnotics and anxiolytics, British Journal of clinical pharmacology, 1911.
, Factors associated with the prescription of antidepressive medication to breast cancer patients, Acta Oncol Stockh Swed. févr, vol.50, issue.2, pp.243-51, 2011.
, Overprescribing proton pump inhibitors, BMJ. 5 janv, vol.336, issue.7634, pp.2-3, 2008.
, Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization, J Manag Care Pharm JMCP. mars, vol.16, issue.2, pp.122-131, 2010.
, Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients, Am J Gastroenterol. oct, vol.101, issue.10, pp.2200-2205, 2006.
, Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?, Int J Clin Pract, vol.66, issue.6, pp.582-91, 2012.
, A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study, J Clin Gastroenterol, vol.45, issue.9, pp.780-784, 2011.
, Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy, Eur J Intern Med. mai, vol.30, pp.31-37, 2016.
, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases -A position paper addressing benefits and potential harms of acid suppression, BMC Med, vol.14, issue.1, p.179, 2016.
, The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal, Eur J Intern Med, vol.37, pp.19-24, 2017.
, The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients, Int J Clin Pharm, vol.1, issue.2015, pp.1152-61
, Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use, Crit Rev Oncol Hematol. mars, vol.111, pp.144-51, 2017.
, Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease, JAMA. 21 déc, vol.294, issue.23, pp.2989-95, 2005.
, Adverse effects of long-term proton pump inhibitor therapy, Dig Dis Sci. avr, vol.56, issue.4, pp.931-50, 2011.
, Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. déc, vol.14, issue.12, pp.1706-1719, 2016.
, The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association, Gastroenterology, vol.152, issue.4, pp.706-721, 2017.
, PharmDPGY-2Community/Academia Pharmacy ResidentKerr Drug/UNC School of PharmacyChapel Hill, North Carolina John A Galdo, PharmD, BCPSClinical Pharmacy Educator, Barney's PharmacyClinical Assistant ProfessorUniversity of Georgia College of PharmacyAugusta. LongTerm Consequences of Chronic Proton Pump Inhibitor Use
,
, Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center, Ann Pharmacother. juill, vol.50, issue.7, pp.541-548, 2016.
, Indications and safety of proton pump inhibitor drug use in patients with cancer, Expert Opin Drug Saf. sept, vol.12, issue.5, pp.659-72, 2013.
, Factors associated with the initiation of proton pump inhibitors in corticosteroid users, Pharmacoepidemiol Drug Saf. avr, vol.21, issue.4, pp.366-74, 2012.
, « A surviving myth »--corticosteroids are still considered ulcerogenic by a majority of physicians, Scand J Gastroenterol, vol.45, issue.10, pp.1156-61, 2010.
, Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy, Br J Clin Pharmacol. août, vol.68, issue.2, pp.252-261, 2009.
, Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients, PloS One, vol.10, issue.11, p.141779, 2015.
, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J Intern Med. déc, vol.236, issue.6, pp.619-651, 1994.
, Overutilization of proton-pump inhibitors: what the clinician needs to know, Ther Adv Gastroenterol. juill, vol.5, issue.4, pp.219-251, 2012.
, Stress Ulcer Prophylaxis in Hospitalized Patients, Subsequent Use in Primary Care, and Physicians' Opinions About Acid-Suppressive Therapy, South Med J. mars, vol.109, issue.3, pp.158-64, 2016.
, Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4791-4800, 2016.
,
, Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors, Br J Cancer, vol.76, issue.6, pp.791-797, 1997.
, Poll-Franse LV van de. The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv
, , vol.8, pp.555-64
, Health-Related Quality of Life Among Survivors of Aggressive Non-Hodgkin Lymphoma, vol.1, pp.672-80
, Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.11, pp.1906-1919, 2015.
, Benzodiazepines and risk of death: Results from two large cohort studies in France and UK, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.10, pp.1566-77, 2015.
, Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD, Eur Respir J. août, vol.44, issue.2, pp.332-372, 2014.
, Hypnotics' association with mortality or cancer: a matched cohort study, BMJ Open, vol.2, issue.1, p.850, 2012.
, Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study, BMJ. 19 mars, vol.348, p.1996, 2014.
, Associations of social and material deprivation with tobacco, alcohol, and psychotropic drug use, and gender: a population-based study, Int J Health Geogr, vol.6, p.50, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00433008
, Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study, Leuk Lymphoma. août, vol.53, issue.8, pp.1474-80, 2012.
, Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a populationbased comparative study, J Cancer Surviv Res Pract. déc, vol.9, issue.4, pp.599-609, 2015.
, Socio-economic implications of cancer survivorship: results from the PROFILES registry, Eur J Cancer Oxf Engl, vol.48, issue.13, pp.2037-2079, 1990.
, The impact of treatment, sociodemographic and clinical characteristics on health-related quality of life among Hodgkin's and nonHodgkin's lymphoma survivors: a systematic review, Ann Hematol. sept, vol.90, issue.9, pp.993-1004, 2011.
, Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, 2017.
, The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv Res Pract. déc, vol.8, issue.4, pp.555-64, 2014.
, Quality of life amongst lymphoma survivors in a developing country, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. déc, vol.24, issue.12, pp.5015-5038, 2016.
, Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity, Br J Cancer. 18 févr, vol.110, issue.4, pp.868-74, 2014.
, Satisfaction with information provision is associated with baseline but not with follow-up quality of life among lymphoma patients: Results from the PROFILES registry, Acta Oncol Stockh Swed. juill, vol.53, issue.7, pp.917-943, 2014.
, Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors--results from a Dutch population-based study, Ann Hematol, vol.91, issue.10, pp.1587-95, 2012.
, Chronic fatigue in long-term survivors of childhood lymphomas and leukemia: persistence and associated clinical factors, J Pediatr Hematol Oncol. août, vol.36, issue.6, pp.438-482, 2014.
, Prevalence and predictors of fatigue in haemo-oncological patients, Intern Med J. oct, vol.44, issue.10, pp.1013-1020, 2014.
, Lymphoma InterVEntion (LIVE) -patient-reported outcome feedback and a web-based self-management intervention for patients with lymphoma: study protocol for a randomised controlled trial, Trials. 28 avr, vol.18, issue.1, p.199, 2017.
, Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy, BMC Cancer, vol.15, p.781, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912614
, Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the Ambulatory Medical Assistance (AMA) experience, Int J Nurs Stud, 2011.
, INVSIncidence et survie des hémopathies malignes: données générales et situation chez les plus de 75 ans, 1989.
, Projections de l'incidence et de la mortalité par cancer en France en 2011. Myélome multiple et maladie immunoproliférative, 2016.
, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, pp.2516-2536, 2008.
, A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR Oncology Good Outcomes Research Practices Working Group, Value Health, vol.16, pp.655-69, 2013.
, Importance of accurately identifying disease in studies using electronic health records, BMJ, vol.341, p.4226, 2010.
, Helping everyone do better: a call for validation studies of routinely recorded health data, Clin Epidemiol, vol.8, pp.49-51, 2016.
, Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhône-Alpes region of France, Rev Epidemiol Sante Pub, vol.54, pp.391-399, 2006.
, Performance evaluation of hospital claims database for the identification of incident central nervous system tumors compared with a cancer registry, Rev Epidemiol Sante Pub, vol.60, pp.295-304, 2004.
, Estimation of national colorectalcancer incidence using claims databases, J Cancer Epidemiol, vol.2012, p.298369, 2012.
, Registre des cancers du Tarn. Health Databases. Available at, 2016.
, International Classification of Diseases for Oncology, 2000.
, Standards and guidelines for cancer registration in Europe. The ENCR recommendations, International Agency for Research on Cancer, vol.1, 2003.
, French health insurance databases: what interest for medical research, Rev Med Interne, vol.36, pp.411-418, 2014.
, Trade-offs between accuracy measures for electronic healthcare data algorithms, J Clin Epidemiol, vol.65, pp.343-352, 2012.
, The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration, Ann Intern Med, vol.138, pp.1-2, 2003.
, Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data, J Clin Epidemiol, vol.64, pp.821-830, 2011.
, Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data, Oncologist, vol.18, pp.37-45, 2013.
, Underreporting of myeloid malignancies by United States cancer registries, Cancer Epidemiol Biomarkers Prev, vol.21, pp.474-81, 2012.
, Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries, Blood, vol.117, pp.7121-7126, 2011.
, Relevance of health administrative databases in cancer surveillance. Comparison with registries records at individual level, Bull Epidemiol Hebd, pp.63-70, 2012.
, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952
, French claims data as a source of information to describe cancer incidence: predictive values of two identification methods of incident prostate cancers, J Med Syst, vol.30, pp.459-63, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00427927
, Algorithme de sélection des hospitalisations liées à la prise en charge du cancer dans les bases nationales d'activité hospitalière de court séjour, 2016.
, Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project, J Am Med Inform Assoc, vol.20, pp.184-92, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01135052
, A systematic review of validated methods for identifying lymphoma using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.203-215, 2012.
, A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.100-128, 2012.
, A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.236-245, 2012.
, A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.248-55, 2012.
, A systematic review of validated methods for identifying infection related to blood products, tissue grafts, or organ transplants using administrative data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.213-234, 2012.
, A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.183-93, 2012.
, A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.174-82, 2012.
, A systematic review of validated methods for identifying transverse myelitis using administrative or claims data, Vaccine, vol.31, issue.10, pp.83-90, 2013.
, Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned, Pharmacoepidemiol Drug Saf, vol.21, issue.1, pp.82-91, 2012.
, Development of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data, 57th American Society of Hematology Annual Meeting, pp.5-8, 2015.
, , vol.96, p.12, 2017.
, Epidemiology of lymphomas, Histopathology, vol.58, issue.1, pp.4-14, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00610747
, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 2013.
, , vol.49, pp.1374-403
, Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 2 -Hémopathies malignes
, New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy, Expert Rev Anticancer Ther, vol.15, issue.5, pp.531-575, 2015.
, Non-Hodgkin lymphoma: diagnosis and treatment, Mayo Clin Proc, 2005.
, Non-Hodgkin Lymphoma: Diagnosis and Treatment, Mayo Clin Proc, vol.90, issue.8, pp.1152-63, 2015.
, Clinical review: Serious adverse events associated with the use of rituximab -a critical care perspective. Crit Care, vol.16, p.231, 2012.
, Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study, Br Med J (Clin Res Ed, vol.295, issue.6604, pp.955-962, 1987.
, What Do We Know About Psychological Outcomes of Lymphoma in Adults, European Psychologist, vol.22, pp.121-131, 2017.
, Economic note: cost of illness studies, BMJ, vol.320, p.1335, 2000.
, Useful for health policy?, PharmacoEconomics, vol.14, pp.143-148, 1998.
, Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health, vol.8, pp.462-70, 2005.
, Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer, vol.14, p.586, 2014.
, Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Appl Health Econ Health Policy, vol.14, pp.465-477, 2016.
, Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation, Pharmacoeconomics, vol.28, issue.1, pp.35-46, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00484797
, Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data, J Med Econ, vol.19, issue.10, pp.965-72, 2016.
, French health insurance databases: What interest for medical research, Rev Med Interne, vol.36, issue.6, pp.411-418, 2015.
, A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. Medicine (Baltimore), vol.97, p.9418, 2018.
, Anatomical Therapeutic Chemical Classification, 2017.
, The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality, Med Care, vol.54, issue.2, pp.188-94, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541
, Bootstrap confidence intervals, vol.11, pp.189-228, 1996.
, Statistical inference in generalized linear mixed models: a review, Br J Math Stat Psychol, vol.59, issue.2, pp.225-55, 2006.
, A Flexible Two-Part Random Effects Model for Correlated Medical Costs J Health Econ, vol.29, pp.110-123, 2010.
, Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review, Pharmacoeconomics, vol.30, issue.7, pp.537-586, 2012.
, The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. Expert Rev Pharmacoecon Outcomes Res, vol.7, pp.319-345, 2007.
, Economic assessment in the management of non-Hodgkin's lymphoma, Expert Opin Pharmacother, vol.5, issue.12, pp.2529-2577, 2004.
, Economic burden of follicular non-Hodgkin's lymphoma, Pharmacoeconomics, vol.27, issue.8, pp.657-79, 2009.
, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, vol.28, issue.27, pp.4184-90, 2010.
, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002.
, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, vol.377, pp.42-51, 2011.
, Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, vol.28, pp.2853-2861, 2010.
, Référentiel Oncomip 2017 Traitement des Lymphomes de l'Adulte, Oncomip treatment guideline of adult lymphomas, 2017.
, Secondary malignancies following cancer chemotherapy, Acta Oncol, vol.33, issue.6, pp.591-599, 1994.
, Non-Hodgkin's lymphoma in women with breast cancer
, Cancer J, 2000.
, , vol.6, pp.336-378
, Guidelines for Hospitalization for Chemotherapy, Oncologist, vol.1, issue.1, pp.107-111, 1996.
, Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network, J Clin Oncol, vol.35, issue.18, pp.2008-2017, 2017.
, Lianne Wennekes et al. Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics, BMC Cancer, vol.15, p.578, 2015.
, Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial, J Clin Oncol, vol.16, pp.3264-3273, 1998.
, Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study, J Clin Oncol, vol.33, issue.23, pp.2516-2538, 2015.
, Emerging therapies in relapsed and refractory peripheral T-cell lymphoma, Clin Adv Hematol Oncol, vol.13, issue.12, pp.837-883, 2015.
, Relapsed Hodgkin lymphoma: management strategies, Curr Hematol Malig Rep, vol.9, issue.3, pp.284-93, 2014.
, Real-world data from the health decision maker perspective. What are we talking about?, Epidemiology Biostatistics and Public Health -2013, vol.10, issue.3, p.115
, Non-cancer drug consumption during the early trajectory of lymphoma survivorship. Thérapie, Annexes, vol.3, issue.17, pp.30186-30191, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907809
, Funding acquisition: Guy Laurent. Methodology: Maryse Lapeyre-Mestre, Guy Laurent, Catherine Rioufoll, Fabien Despas, Cyrille Delpierre. Resources: Maryse Lapeyre-Mestre, Fabien Despas, Guy Laurent. Software: Catherine Rioufoll, Sébastien Lamy, Cyrille Delpierre, Cécile conte. Supervision: Maryse Lapeyre-Mestre, Fabien Despas, Guy Laurent. Validation: All authors. Writing -original draft: Catherine Rioufoll, Conceptualization: Maryse
, Consulting and prescribing behaviour for anxiety and depression in long-term survivors of cancer in the UK, Eur J Cancer, vol.46, issue.18, pp.3339-3383, 2010.
, Determinants of increased primary health care use in cancer survivors, J Clin Oncol, vol.30, issue.33, pp.4155-60, 2012.
, Ambulatory medical assistance-after cancer (AMA-AC): a model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy, BMC Cancer, vol.15, p.781, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01912614
, Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, issue.5, pp.579-86, 2007.
, , 2016.
, Overcoming problems with polypharmacy and drug misuse in the elderly, Clin Geriatr Med, vol.8, issue.1, pp.143-58, 1992.
, Polypharmacy in elderly patients, Am J Geriatr Pharmacother, vol.5, issue.4, pp.345-51, 2007.
, Validation de la version française du HADS dans une population de patients cancéreux hospitalisés, Rev Psychol Appliquee, vol.39, issue.4, pp.295-307, 1989.
, The hospital anxiety and depression scale, Acta Psychiatr Scand, vol.67, issue.6, pp.361-70, 1983.
, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, vol.109, issue.5, pp.1857-61, 2007.
, Follicular lymphoma international prognostic index, Blood, vol.104, issue.5, pp.1258-65, 2004.
, A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease, N Engl J Med, vol.339, issue.21, pp.1506-1520, 1998.
, Evolution of drug consumption in a sample of French workers since 1986: the 'Drugs and Work' study, Pharmacoepidemiol Drug Saf, vol.18, issue.4, pp.335-378, 2009.
, Trends in prescription drug use among adults in the United States from 1999-2012, JAMA, vol.314, issue.17, pp.1818-1849, 2015.
, Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method, Expert Opin Drug Saf, vol.15, issue.2, pp.223-259, 2016.
, Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea, World J Gastroenterol, vol.16, issue.28, pp.3573-3580, 2010.
, Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study, Pharmacoepidemiol Drug Saf, vol.19, issue.8, pp.792-802, 2010.
, Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients, Gastroenterology, vol.139, issue.1, pp.93-101, 2010.
, Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study
, Br J Cancer, vol.107, pp.1644-51, 2012.
, Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands, Psychooncology, vol.22, pp.762-769, 2013.
, Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database, Support Care Cancer, vol.24, issue.11, pp.4791-4800, 2016.
, Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors, J Clin Oncol, vol.26, issue.6, pp.934-975, 2008.
, Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis
, Ann Oncol, vol.21, issue.5, pp.925-955, 2010.
, Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological
, Non-cancer drug consumption during the early trajectory of lymphoma survivorship, Therapie, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01907809
, ARTICLE IN PRESS +Model THERAP, vol.216, p.11
, Non-cancer drug in lymphoma survivors 11 settings: a meta-analysis of 94 interview-based studies, Lancet Oncol, vol.12, issue.2, pp.160-74, 2011.
, Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project, Acta Psychiatr Scand Suppl, vol.420, pp.55-64, 2004.
, Patterns of psychiatric medication use among nationally representative long-term cancer survivors and controls, Cancer, vol.121, issue.1, pp.132-140, 2015.